Cardiovascular Prevention Clinical Trial
Official title:
Cardiovascular Prevention Program at Maria Cecilia Hospital
Verified date | March 2024 |
Source | Maria Cecilia Hospital |
Contact | Elena Tenti |
Phone | 0545217031 |
etenti[@]gvmnet.it | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cardiovascular diseases represent one of the main public health problems being the leading cause of morbidity, disability and mortality. In recent decades, the global prevalence and cardiovascular disease mortality has increased, with 23.6 million annual deaths expected by 2030. In Europe, mortality per year is equal to 2.2 million women and 1.9 million men, representing 47% and 37% of all deaths respectively. In Italy, the situation in terms of deaths due to cardiovascular diseases it is in line with the world ranking and European, being responsible for 44% of all deaths. The only interventional or pharmacological approach is neither effective nor sustainable. The most deaths from cardiovascular diseases are due to atherothrombotic events, which are attributable to a series of risk factors, most of which are modifiable. Turns out itself as a targeted action on these factors with the aim of safeguarding the state of health cardiovascular, may represent the best applicable strategy. It is therefore necessary structure and activate prevention programs aimed at the general population and groups of subjects at higher risk.
Status | Not yet recruiting |
Enrollment | 150 |
Est. completion date | April 15, 2027 |
Est. primary completion date | April 15, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility | Inclusion Criteria: - primary prevention: age = 30 years with a negative history of cardiovascular events - secondary prevention: age = 30 years with a negative history of cardiovascular events Exclusion Criteria: - severe obesity - high-grade renal failure - severe and/or dialysis - oncological disease in active phase - pregnancy |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Maria Cecilia Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | measure of body mass index | BMI Assessment | 12 months | |
Primary | Adherence to the Mediterranean diet | Mediterranean Diet Adherence | 12 months | |
Primary | blood test to check cholesterol levels | Assessment of hypercholesterolemia | 12 months | |
Primary | blood pressure measurement | Evaluation of Diastolic Blood Pressure | 12 months | |
Primary | blood glucose test | evaluation of blood glucose | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01888575 -
Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy
|
N/A | |
Recruiting |
NCT06284850 -
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
|
||
Recruiting |
NCT05884840 -
New Cardiovascular Risk Screening Strategy.
|
N/A | |
Enrolling by invitation |
NCT04450914 -
Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP)
|
N/A | |
Completed |
NCT03488797 -
Web-based Motor Intervention to Increase Health Related Physical Fitness in Children With Congenital Heart Disease
|
N/A | |
Recruiting |
NCT05659498 -
Cardiac Rehabilitation for Cardiovascular Risk Reduction in People With Severe and Persistent Mental Illness
|
N/A | |
Recruiting |
NCT05226806 -
Connect2Move: Valorization of Natural Cardio Trekking Hiking Trails
|